AAN 2021 | SEP-363856: a future option for Parkinson’s disease psychosis

Stuart Isaacson, MD, FAAN, Parkinson Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, comments on the benefits of having treatment options, such as SEP-363856, for Parkinson’s disease (PD) psychosis. Many PD patients develop psychotic symptoms at a very early stage, and the symptoms worsen over time. Currently, there is only one on-label first-line medication that can treat psychosis without compromising the motor symptoms treatment. Therefore, if SEP-363856 becomes commercially available, it will play an important role in PD psychosis treatment. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.